Randomised Trial in Waldenstrom's Macroglobulinaemia
Status:
Completed
Trial end date:
2020-08-02
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to assess tolerability and efficacy of the Bortezomib,
Cyclophosphamide and Rituximab combination as initial therapy for previously untreated
patients with symptomatic Waldenstrom's macroglobulinaemia.